However, despite the promising survival data, accumulating evidence from real-world investigations suggests that most patients with metastatic melanoma harboring a BRAF-mutation will at some timepoint show a relapse of the disease, which requires the re-initiation of anti-tumor treatments due to primary or acquired tumor resistance [9]. This evidence concerns the gene BRAF and metastatic melanoma.